The biotechnology group noted that Feldmann has a “unique blend of scientific, medical and commercial experience and expertise”, pointing out that he shares the academic credit for inventing and developing an anti-TNF therapy for rheumatoid arthritis - the first use of monoclonal antibodies in a common disease.
HemoGenyx said Feldmann was previously chairman of the company’s scientific advisory board and has a “remarkably broad experience” of discovering new medicines, testing ideas and leading clinical trials.
Following the changes, Robin Campbell, currently Hemogenyx's chairman, will become a non-executive director and Adrian Beeston, its non-executive director, will step down from the board, both with the immediate effect.
Vladislav Sandler, HemoGenyx's CEO, said: “Since Sir Marc has been at the forefront of promoting effective scientific-medical-pharmaceutical interactions, he has built up a huge network of friends and collaborators who meet regularly in Oxford and they will help Hemogenyx grow and go clinical.”
In early morning trading, the company’s shares were up 6.4% at 2.90p.